相关实验视频
Updated: Feb 13, 2026

06:14
Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
Published on: May 13, 2021
7.5K
战略性地设计一种瘤性简单疹病毒,以改善系统性输送
Xinping Fu1, Tomasz Benedyk1, Shaun Xiaoliu Zhang1
1Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, USA.
Molecular therapy. Oncology
|February 12, 2026
概括
FusOn-SD是一种改性瘤病毒,克服了系统性癌症病毒疗法的挑战. 它避免了免疫清除和抗体中和,显示出治疗转移性瘤的前景.
科学领域:
- 瘤治疗性病毒疗法
- 癌症免疫疗法癌症免疫疗法
- 病毒瘤学 病毒瘤学
背景情况:
- 瘤解毒性病毒疗法 (OV) 使用病毒向并摧毁癌细胞,刺激抗瘤免疫力.
- 目前的OV治疗仅限于内注射,这阻碍了转移性或难以接近的瘤的治疗.
- 系统性输送面临着由单核细胞系统 (MPS) 快速清除和抗病毒抗体中和的挑战.
研究的目的:
- 开发一种增强型瘤性病毒,FusOn-SD,用于有效的全身传递.
- 设计FusOn-SD以逃避免疫清除和抗体中和,以提高疗效.
- 评估FusOn-SD在通过全身注射治疗转移性癌症方面的潜力.
主要方法:
- 对FusOn-H2进行基因改造,以结合CD47细胞外域 (ECD) 来避免MPS.
- 通过免疫血清的连续传递进行适应性修饰,以增加对中和抗体的抵抗力.
- 在全身注射后,对FusOn-SD的生物分布,免疫逃避和瘤解毒功能的临床前评估.
主要成果:
- 在全身用药后,FusOn-SD证明了有效的瘤向.
- 工程病毒表现出增强的免疫逃避能力.
- 与未经修改的病毒相比,FusOn-SD显示其抗瘤作用强度增加.
- 临床前研究证实了FusOn-SD在全身癌症病毒治疗中的潜力.
结论:
- FusOn-SD代表了瘤性病毒疗法的重大进步,克服了系统性输送的关键障碍.
- 这种增强的病毒对治疗转移性和难以接近的瘤充满希望,扩大了OV的临床应用.
- FusOn-SD可以将瘤性病毒疗法转化为晚期癌症的可行的全身治疗选择.
相关概念视频
Transdermal Drug Delivery Systems
3
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
3
Ophthalmic Drug Delivery Systems
1
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
1
Intrauterine Drug Delivery Systems
1
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
1
Drug Delivery Systems: Different Types
1
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
1
Oral Drug Delivery Systems: Continuous-Release Systems
1
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
1
Oral Drug Delivery Systems: Delayed-Release Systems
2
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
2

